# Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

> **NCT03376477** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 24 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** GM-CSF vaccine
- **DRUG:** Lenalidomide
- **DRUG:** Prevnar13
- **OTHER:** Placebo Prevnar13
- **OTHER:** Placebo GM-CSF Vaccine

## Key facts

- **NCT ID:** NCT03376477
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-23
- **Primary completion:** 2024-01-02
- **Final completion:** 2025-05-30
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** loss of funding
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03376477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03376477, "Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03376477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*